Paper Details

  1. Home
  2. Paper Details

Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up.

Author: CaoWenyue, ChenLiting, ChengJiali, HuangJin, HuangLiang, MaoXia, WangNa, ZhouJianfeng

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Cytomegalovirus (CMV) is a common virus that can cause serious complications in immunocompromised patients, such as those receiving CAR-T cell therapy. This case report describes a patient who developed possible CMV-pneumonia three months after receiving CAR-T cell therapy.
Paper Details　
Original Abstract of the Article :
The rapidly developed CAR-T cell therapy has a unique profile of side effects, which perhaps has not been totally realized and understood, especially the late-phase toxicity. CMV is prevalent world-wide and establishes a life-long latency infection. It can lead to life-threatening complications in i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577281/

データ提供：米国国立医学図書館（NLM）

Fatal Cytomegalovirus Pneumonia After CAR-T Cell Therapy: A Case Report

This case report delves into a potentially serious complication of [CAR-T cell therapy], a rapidly evolving treatment for various cancers. The report describes a patient who developed fatal cytomegalovirus (CMV) pneumonia three months after receiving CAR-T cell therapy for relapsed B-cell acute lymphoblastic leukemia (B-ALL). The report highlights the potential for CMV reactivation as a late-phase toxicity of CAR-T cell therapy, underscoring the importance of understanding and managing this complication in patients receiving this treatment.

CMV Reactivation: A Potential Complication of CAR-T Cell Therapy

The findings of this case report emphasize the importance of vigilance in monitoring for CMV reactivation in patients undergoing CAR-T cell therapy. This research highlights the need for proactive strategies to prevent and manage CMV reactivation, especially in immunocompromised individuals.

Navigating CAR-T Cell Therapy: A Delicate Balance

This case report underscores the potential challenges associated with CAR-T cell therapy, a promising but complex treatment. It highlights the importance of understanding the potential side effects, especially late-phase toxicities, and the need for ongoing research to optimize treatment regimens and manage potential complications. Just as a camel navigates the desert landscape, managing CAR-T cell therapy requires a delicate balance of careful monitoring and proactive intervention.

Dr.Camel's Conclusion

This case report highlights the potential for CMV reactivation as a late-phase toxicity of CAR-T cell therapy. It underscores the importance of understanding and managing this complication in patients receiving this treatment.

Date :
  1. Date Completed 2023-10-23
  2. Date Revised 2023-10-23
Further Info :

Pubmed ID

37849765

DOI: Digital Object Identifier

PMC10577281

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.